Clinical studies of extended-half-life recombinant FVIII products for prophylaxis in adults and children: a critical review from the physician's perspective.
Sign Up to like & getrecommendations! Published in 2022 at "Critical reviews in oncology/hematology"
DOI: 10.1016/j.critrevonc.2022.103678
Abstract: This review compares the methodology of published clinical studies investigating the extended-half-life (EHL) factor VIII (FVIII) products, rFVIIIFc (efmoroctocog alfa, Elocta®/Eloctate®), BAY 94-9027 (damoctocog alfa pegol, Jivi®), BAX 855 (rurioctocog alfa pegol, Adynovate®) and N8-GP… read more here.
Keywords: clinical studies; methodology; fviii products; life ... See more keywords
An extended half-range spherical harmonics method for first-order neutron transport equation based on variational treatment
Sign Up to like & getrecommendations! Published in 2017 at "Progress in Nuclear Energy"
DOI: 10.1016/j.pnucene.2017.07.010
Abstract: Abstract A new variational approach with anisotropic scattering kernel for first order neutron transport equation based on Finite Element Method (FEM) and Double- P N ( DP N ) approximation has been introduced. In presented… read more here.
Keywords: neutron; extended half; transport equation; geometry ... See more keywords
Bleeding outcomes and factor utilization after switching to an extended half-life product for prophylaxis in haemophilia A in Austria
Sign Up to like & getrecommendations! Published in 2021 at "Scientific Reports"
DOI: 10.1038/s41598-021-92245-5
Abstract: To prevent bleeding in severe haemophilia A [SHA, defined as factor VIII (FVIII) activity read more here.
Keywords: extended half; outcomes factor; prophylaxis; factor utilization ... See more keywords
Pharmacokinetics of a novel extended half‐life glycoPEGylated factor IX, nonacog beta pegol (N9‐GP) in previously treated patients with haemophilia B: results from two phase 3 clinical trials
Sign Up to like & getrecommendations! Published in 2017 at "Haemophilia"
DOI: 10.1111/hae.13191
Abstract: Nonacog beta pegol (N9‐GP) is a glycoPEGylated recombinant factor IX (FIX) with an extended half‐life developed for routine prophylaxis and the prevention and treatment of bleeding episodes in patients with haemophilia B. read more here.
Keywords: extended half; patients haemophilia; beta pegol; nonacog beta ... See more keywords
First report on the safety and efficacy of an extended half‐life glycoPEGylated recombinant FVIII for major surgery in severe haemophilia A
Sign Up to like & getrecommendations! Published in 2017 at "Haemophilia"
DOI: 10.1111/hae.13246
Abstract: N8‐GP (turoctocog alfa pegol) is an extended half‐life glycoPEGylated recombinant factor VIII (FVIII) product developed for the prevention and treatment of bleeds in haemophilia A patients. read more here.
Keywords: glycopegylated recombinant; extended half; life glycopegylated; haemophilia first ... See more keywords
Regional variation and cost implications of prescribed extended half‐life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe haemophilia
Sign Up to like & getrecommendations! Published in 2019 at "Haemophilia"
DOI: 10.1111/hae.13758
Abstract: Extended half‐life (EHL) factor VIII (FVIII) and IX (FIX) products are intended to decrease the burden of prophylaxis for patients with haemophilia A or B. Whether these newer concentrates have led to meaningful clinical practice… read more here.
Keywords: extended half; haemophilia regional; regional variation; factor ... See more keywords
Real‐life experience in switching to new extended half‐life products at European haemophilia centres
Sign Up to like & getrecommendations! Published in 2019 at "Haemophilia"
DOI: 10.1111/hae.13834
Abstract: The concept of replacement therapy in haemophilia is changing significantly thanks to the switch from standard products to extended half‐life products. These novel drugs are showing beneficial effects overcoming current prophylaxis limitations by reducing the… read more here.
Keywords: extended half; haemophilia; half life; life products ... See more keywords
Invasive procedures in patients with haemophilia: Review of low‐dose protocols and experience with extended half‐life FVIII and FIX concentrates and non‐replacement therapies
Sign Up to like & getrecommendations! Published in 2020 at "Haemophilia"
DOI: 10.1111/hae.13978
Abstract: The performance of surgery and invasive procedures in patients with haemophilia is currently facing new challenges globally. The first is the appropriate application of low‐dose protocols of clotting factor concentrates (CFC) achieving adequate perioperative haemostasis… read more here.
Keywords: procedures patients; extended half; low dose; life ... See more keywords
Clinical application of extended half‐life factor VIII in children with severe haemophilia A
Sign Up to like & getrecommendations! Published in 2022 at "Haemophilia"
DOI: 10.1111/hae.14576
Abstract: Only few studies have presented results from real‐world clinical use of Extended Half‐Life (EHL) products in children with haemophilia (CWH). read more here.
Keywords: haemophilia clinical; clinical application; application extended; half life ... See more keywords
Surgical outcomes in patients with haemophilia A or B receiving extended half‐life recombinant factor VIII and IX Fc fusion proteins: Real‐world experience in the Nordic countries
Sign Up to like & getrecommendations! Published in 2022 at "Haemophilia"
DOI: 10.1111/hae.14585
Abstract: Perioperative dosing recommendations vary across Nordic haemophilia treatment centres (HTCs) for extended half‐life (EHL) factor concentrates in haemophilia A/B (HA/HB) patients. read more here.
Keywords: surgical outcomes; half life; patients haemophilia; factor ... See more keywords
LongHest project: A prospective, observational study of extended half‐life treatment in the musculoskeletal health of patients with severe haemophilia A
Sign Up to like & getrecommendations! Published in 2022 at "Haemophilia"
DOI: 10.1111/hae.14592
Abstract: Prophylactic treatment is the gold standard in the treatment of patients with haemophilia. Prophylaxis with extended half‐life (EHL) treatment has shown long‐term safety and efficacy in patients with haemophilia. read more here.
Keywords: longhest project; haemophilia longhest; half life; extended half ... See more keywords